Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)

Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)

US Patent 10059708 · Granted Aug 28, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Therapeutic targeting of the BAP1 complex in cancer2023
Small molecules for disrupting the super elongation complex and inhibiting trans2022
Small molecules for disrupting the super elongation complex and inhibiting trans2022
Small molecules for disrupting the super elongation complex and inhibiting trans2022
Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene2021
Therapeutic targeting of SET1B/compass pathway for treating cancers2021
Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in c2020
Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in c2020
Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in c2020
Therapeutic targeting of SET1B/compass pathway for treating cancers2019
ELL2, a new member of an ELL family of RNA polymerase II elongation factors2002
ELL2, a new member of an ELL family of RNA polymerase II elongation factors1999